Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain
- 21 June 2013
- journal article
- Published by Springer Science and Business Media LLC in Clinical and Translational Oncology
- Vol. 16 (3), 273-279
- https://doi.org/10.1007/s12094-013-1068-3
Abstract
The standard adjuvant treatment for glioblastoma is temozolomide concomitant with radiotherapy, followed by a further six cycles of temozolomide. However, due to the lack of empirical evidence and international consensus regarding the optimal duration of temozolomide treatment, it is often extended to 12 or more cycles, even in the absence of residual disease. No clinical trial has shown clear evidence of clinical benefit of this extended treatment. We have explored the economic impact of this practice in Spain.Keywords
This publication has 22 references indexed in Scilit:
- Patterns of care and outcome for patients with glioblastoma diagnosed during 2008–2010 in SpainNeuro-Oncology, 2013
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009Neuro-Oncology, 2012
- Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiformeJournal of Neuro-Oncology, 2012
- Controversies in the Adjuvant Therapy of High-Grade GliomasThe Oncologist, 2011
- Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United StatesClinical Cancer Research, 2010
- Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004Neuro-Oncology, 2010
- MGMT promoter methylation in malignant gliomas: ready for personalized medicine?Nature Reviews Neurology, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Adjuvant temozolomide: how long and how much?Expert Review of Anticancer Therapy, 2008
- Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapseAnnals of Oncology, 2001